The Mag

Cancer Immunotherapy, Financing in Europe, Adaptive Pathways, Biosimilars

In this issue:

  • Cancer Immunotherapy: Natural Born Killers
  • Financing in Europe: Good numbers, but investors are anxious about the future
  • Adaptive Pathways: Testing the new superhighway to rapid patient access
  • Biosimilars: Will EU labelling guidelines cripple their market success?
  • Interview with Richard Mason, Head of J&J’s Innovation Centre in London
  • News from our partner associations European Biotechnology Network, EAPB, EDMA, DIA, BIO Deutschland and the Swiss Biotech Association
  • ... and our special EU Event Compass.